By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Cara Therapeutics, Inc. 

One Parrott Drive

Shelton  Connecticut  06484  U.S.A.
Phone: 203-567-1500 Fax: 203-567-1510


SEARCH JOBS


Industry
Biotechnology

Segment
Start Up





Company News
Cara Therapeutics, Inc. (CARA) To Sponsor Symposium And Present Posters At PAINWeek 9/1/2015 12:30:02 PM
Enteris Biopharma's Formulation Technology Enables Oral Delivery Of Cara Therapeutics, Inc. (CARA)' CR845 Peptide In Phase 2 Trial In Osteoarthritis 8/20/2015 8:33:52 AM
Cara Therapeutics, Inc. (CARA) Initiates Phase II Trial Of Oral CR845 In Osteoarthritis 8/17/2015 6:17:49 AM
Cara Therapeutics, Inc. (CARA) Reports Second Quarter 2015 Financial Results 8/11/2015 12:23:06 PM
Cara Therapeutics, Inc. (CARA) Announces Closing Of Its Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares 8/5/2015 7:13:16 AM
Cara Therapeutics, Inc. (CARA) Announces Pricing Of Its Public Offering Of Common Stocks 7/30/2015 7:06:49 AM
Cara Therapeutics, Inc. (CARA) Announces Proposed Offering Of Common Stock 7/28/2015 7:15:35 AM
Cara Therapeutics, Inc. (CARA) Soars 35% on Positive Phase II Uremic Pruritus Data 7/23/2015 7:29:19 AM
Enteris Biopharma Oral Formulation Progresses Into Phase 2 Study With Cara Therapeutics, Inc. (CARA)' CR845 7/14/2015 11:21:12 AM
Cara Therapeutics, Inc. (CARA) Completes Enrollment Of Phase 2 Trial Of I.V. CR845 In Uremic Pruritus 6/23/2015 6:17:23 AM
1234567
//-->